Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $1,134,600.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $75.64, for a total value of $1,134,600.00. Following the completion of the sale, the chief executive officer now directly owns 478,888 shares in the company, valued at $36,223,088.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Grant Pickering also recently made the following trade(s):

• On Monday, June 3rd, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $72.06, for a total transaction of $188,508.96.
• On Thursday, May 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.43, for a total value of $1,041,450.00.
• On Tuesday, April 23rd, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $61.92, for a total value of $928,800.00.

Vaxcyte Trading Up 5.0 %

Shares of NASDAQ:PCVX opened at $78.77 on Friday. Vaxcyte, Inc. has a 52 week low of $44.20 and a 52 week high of $82.04. The company’s 50 day moving average is $69.30 and its two-hundred day moving average is $67.74. The company has a market cap of $8.57 billion, a PE ratio of -18.40 and a beta of 0.97.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.28. As a group, equities research analysts expect that Vaxcyte, Inc. will post -3.96 EPS for the current year.

Analyst Ratings Changes

PCVX has been the topic of a number of recent analyst reports. Needham & Company LLC reiterated a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a report on Thursday, May 9th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Darwin Global Management Ltd. increased its position in shares of Vaxcyte by 374.3% in the first quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after buying an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Vaxcyte by 15.2% in the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Westfield Capital Management Co. LP purchased a new position in shares of Vaxcyte during the 3rd quarter worth approximately $51,180,000. Norges Bank acquired a new position in shares of Vaxcyte during the 4th quarter worth approximately $57,494,000. Finally, Capital Research Global Investors lifted its stake in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after buying an additional 700,414 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.